Dr. Thomas Madden
President & CEO
Dr. Thomas D. Madden is the President and CEO of Acuitas Therapeutics. He is a world-renowned expert in nanotechnology. He co-founded Acuitas in 2009 and has guided the company into its position as the global leader in lipid nanoparticle (LNP) delivery technology.
Tom has more than 60 publications in peer-reviewed journals related to LNP technology and the development of pharmaceutical products, including recent publications in Nature. In 2020, he was made a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) in recognition of his contributions to the field of nucleic acid delivery.
Along with Acuitas Therapeutics’ co-founders (Drs. Pieter Cullis and Michael Hope), Tom was recognized by the 2022 Governor General’s Innovation Award. They received this prestigious award for developing LNP delivery systems for nucleic acid drugs.